According to PatientView’s newly released “Corporate Reputation of Pharma – From the Patient Perspective,” the majority of people tend to hold a negative or indifferent view of the pharmaceutical industry’s reputation.
There is something of a recurring theme among the life science, healthcare and biopharma industries: a shortage of skilled employees will lead to a decrease in innovation.
Nocion Therapeutics launched in Cambridge, Mass., with a $27 million series A raise this week.
The White House is expanding its war on opioid addiction with a $350 million addiction research and treatment initiative.
Privately held Talaris Therapeutics secured $100 million in a Series A financing round as the company undergoes a rebranding with a new leadership team.
With a $75 million infusion of new financing, Massachusetts-based Arrakis Therapeutics will focus the company’s pipeline on oncology and genetically validated targets in other diseases.
U.S. Food and Drug Administration Acting Commissioner Ned Sharpless said he plans to “maintain FDA’s current course of action in every area and proceed full-speed ahead,” according to a statement issued by the regulatory agency.
Inside Look: Janssen’s HBV Asset Licensed From Arrowhead Could Become Treatment Franchise Cornerstone
Six months after forging a hepatitis B drug development deal valued at more than $3.7 billion with Arrowhead Pharmaceuticals, Janssen Pharmaceutical presented data that showed the RNA interference (RNAi) therapeutic candidate exhibited robust effects on the liver disease that takes the lives of more than 900,000 people annually.
PureTech Health signed a research collaboration deal with Germany’s Boehringer Ingelheim to develop novel product candidates using the Boston-based and London-listed company’s proprietary lymphatic targeting technology for immune modulation.
Axsome Therapeutics announced that the New York City-based company’s AXS-05 met the primary endpoint for smoking cessation treatment.